Page 2 - Pharma Stocks

SMS Pharma up 8% as arm gets USFDA nod for reformulated Ranitidine tablets

At 10:40 AM, SMS Pharmaceuticals share price was trading 6.77 per cent higher at ₹292.55 per share. In comparison, BSE Sensex was trading 0.73 per cent higher at 85,204.25 levels.

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

Glenmark Pharma stock gains 3% on launch novel COPD treatment; details here

The company has launched Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, world's first nebulised, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

IT, pharma to gain most from rupee fall; don't jump to buy yet: Analysts

On Monday, the rupee advanced amid reports that the RBI resumed efforts to support currency via overseas and onshore markets

Glenmark Pharma shares rise after 72% Q2 profit jump; check outlook here

Glenmark Pharma shares rose after the company reported a 72.2 per cent surge in profit after tax to ₹610.43 crore in September quarter

Ipca Labs jumps 7% after Q2 results; buy, sell or hold? Analysts suggest

Ipca Laboratories share price was trading 6.2 per cent higher at ₹1,382.60 compared to previous session's close of ₹1,302 on the NSE

Lupin share rises 2% as arm commissions Oncology block at Vizag facility

At 1:15 PM, Lupin share price was trading 1.90 per cent higher at ₹2,013.20 per share. In comparison, BSE Sensex was trading 0.91 per cent higher at 84,632.82 levels.

Nomura lifts Lupin target price on US momentum, India growth recovery

However, on the bourses, Lupin shares were trading 0.70 per cent lower at ₹1,973.50 per share at 9:30 AM. In comparison, BSE Sensex was trading 0.23 per cent lower at 83,346.45 levels.

Zydus Life Q2: Solid beat on bottom line, analysts mixed on growth outlook

Zydus Life Q2 results review: Foreign brokerage Nomura said Zydus Life delivered results above estimates, led by a stronger-than-expected performance in India.

Sun Pharma Q2 preview: Profit may dip YoY despite revenue growth; details

Sun Pharma's net profit is expected to come at ₹2,843.4 crore, marking an average decline of 3 per cent Y-o-Y, as against ₹2,932.3 crore in the year-ago period

Ajanta Pharma offers growth potential amid US generic challenges: Nuvama

With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth

Motilal Oswal initiates with 'Buy' on Rubicon Research; check target

Motilal Oswal has initiated coverage on Rubicon Research, a pharmaceutical manufacturing company, with a 'Buy' rating

Cipla Q2 revenue grows, margins squeeze; analysts decode stock strategy

In the Q2FY26, Cipla reported consolidated revenue from operations of ₹7,589 crore, up 8 per cent year-on-year (Y-o-Y) from ₹7,051 crore in the year-ago period

Dr Reddy's plunges 6%, hits 5-month low; why pharma stock under pressure?

Dr Reddy's Laboratories has received a Notice of Non-Compliance from Pharmaceutical Drugs Directorate, Canada, regarding its Abbreviated New Drug Submission for Semaglutide Injection.

Cipla Q2 preview: Pharma major may see stable qtr; check key estimates here

Cipla is expected to report a profit after tax (PAT) of ₹1,361.6 crore for the September 2025 quarter, against ₹1,302.5 crore in Q2FY25

Sigachi Industries stock falls 4% after weak Q2; net profit down 50% YoY

Sigachi Industries reported revenue from operations of ₹113 crore in Q2FY26, down 19 per cent from ₹139.5 crore in the year-ago period

Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Nuvama retains 'Hold' on Cipla, raises target after Eli Lilly diabetes deal

Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.

Dr Reddy's Q2 preview: Profit may moderate as US sales dip; check estimates

Dr Reddy's net profit is expected to come at ₹1,479 crore, marking a moderate 5.5 per cent Y-o-Y increase, on average, as against ₹1,401 crore in the year-ago period